Case management of the anemic patient: epoetin alfa--focus on osteitis fibrosa.
Most patients with anemia caused by end-stage renal disease respond well to Epoetin alfa therapy, but in a small number the hematocrit fails to rise as expected. A potential cause of suboptimal response is osteitis fibrosa. Understanding the pathophysiology, manifestations, diagnosis, and treatment for osteitis fibrosa helps nurses to identify this condition as a cause of resistance to Epoetin alfa and to manage patients appropriately.
Morley
C T
CT
D000328:Adult; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D002118:Calcium / Q000097:blood / Q000378:metabolism; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000097:blood / Q000150:complications* / Q000378:metabolism; D004921:Erythropoietin / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D010758:Phosphorus / Q000097:blood / Q000378:metabolism
D004921:Erythropoietin; D010758:Phosphorus; D002118:Calcium